BUSCADOR RECOLECTA

Humans have a great diversity in phenotypes, influenced by genetic, environmental, nutritional, cultural, and social factors. Understanding the historical trends of physiological traits can shed light on human physiology, as well as elucidate the factors that influence human diseases. Here we built genome-wide polygenic scores for heritable traits, including height, body mass index, lipoprotein concentrations, cardiovascular disease, and intelligence, using summary statistics of genome-wide association studies in Europeans. Subsequently, we applied these scores to the genomes of ancient European populations. Our results revealed that after the Neolithic, European populations experienced an increase in height and intelligence scores, decreased their skin pigmentation, while the risk for coronary artery disease increased through a genetic trajectory favoring low HDL concentrations. These results are a reflection of the continuous evolutionary processes in humans and highlight the impact that the Neolithic revolution had on our lifestyle and health., Peer reviewed

Humans have a great diversity in phenotypes, influenced by genetic, environmental, nutritional, cultural, and social factors. Understanding the historical trends of physiological traits can shed light on human physiology, as well as elucidate the factors that influence human diseases. Here we built genome-wide polygenic scores for heritable traits, including height, body mass index, lipoprotein concentrations, cardiovascular disease, and intelligence, using summary statistics of genome-wide association studies in Europeans. Subsequently, we applied these scores to the genomes of ancient European populations. Our results revealed that after the Neolithic, European populations experienced an increase in height and intelligence scores, decreased their skin pigmentation, while the risk for coronary artery disease increased through a genetic trajectory favoring low HDL concentrations. These results are a reflection of the continuous evolutionary processes in humans and highlight the impact that the Neolithic revolution had on our lifestyle and health., Peer reviewed

The file contains: data analysis, results, 1 table and 3 figures., Methods and Results post-hoc modeling of individual trait dispersion (SES) against environmental predictors., Peer reviewed

The file contains 3 tables and 8 figures., Peer reviewed

Herein we show that dispersing inorganic cesium lead bromide (CsPbBr3) perovskite quantum dots (QDs) in optical quality films, possessing an accessible and controlled pore size distribution, gives rise to fluorescent materials with a controlled and highly sensitive response to ambient changes. A scaffold-based synthesis approach is employed to obtain ligand-free QDs, whose pristine surface endows them with high sensitivity to the presence of different vapors in their vicinity. At the same time, the void network of the host offers a means to gradually expose the embedded QDs to such vapors. Under these conditions, the luminescent response of the QDs is mediated by the mesostructure of the matrix, which determines the rate at which vapor molecules will adsorb onto the pore walls and, eventually, condensate, filling the void space. With luminescence quantum yields as high as 60%, scaffold-supported ligand-free perovskite nanocrystals display intense photoemission signals over the whole process, as well as high photo- and chemical stability, which allows illuminating them for long periods of time and recovering the original response upon desorption of the condensed phase. The results herein presented open a new route to explore the application of perovskite QD-based materials in sensing., Peer reviewed

Figure S1: 1H-NMR (500 MHz, CDCl3) Spectrum of Compound 1 Figure S2: 13C-NMR (125 MHz, CDCl3) Spectrum of Compound 1 Figure S3: ESI-MS Spectrum of Compound 1 Figure S4: HRHRESI-MS Spectrum of Compound 1 Figure S5: 1H-NMR (500 MHz, CDCl3) Spectrum of Compound 2 Figure S6: 13C-NMR (125 MHz, CDCl3) Spectrum of Compound 2 Figure S7: ESI-MS Spectrum of Compound 2 Figure S8: HRESI-MS Spectrum of Compound 2 Figure S9: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 3 Figure S10: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 3 Figure S11: ESI-MS Spectrum of Compound 3 Figure S12: HRESI-MS Spectrum of Compound 3 Figure S13: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 4 Figure S14: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 4 Figure S15: ESI-MS Spectrum of Compound 4 Figure S16: HRESI-MS Spectrum of Compound 4 Figure S17: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 5 Figure S18: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 5 Figure S19: ESI-MS Spectrum of Compound 5 Figure S20: HRESI-MS Spectrum of Compound 5 2 Figure S21: 1H-NMR (500 MHz, CDCl3) Spectrum of Compound 6 Figure S22: 13C-NMR (126 MHz, CDCl3) Spectrum of Compound 6 Figure S23: ESI-MS Spectrum of Compound 6 Figure S24: HRESI-MS Spectrum of Compound 6 Figure S25: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 7 Figure S26: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 7 Figure S27: ESI-MS Spectrum of Compound 7 Figure S28: HRESI-MS Spectrum of Compound 7 Figure S29: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 8 Figure S30: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 8 Figure S31: ESI-MS Spectrum of Compound 8 Figure S32: HRESI-MS Spectrum of Compound 8 Figure S33: 1H-NMR (500 MHz, CDCl3) Spectrum of Compound 9 Figure S34: 13C-NMR (126 MHz, CDCl3) Spectrum of Compound 9 Figure S35: ESI-MS Spectrum of Compound 9 Figure S36: HRESI-MS Spectrum of Compound 9 Figure S37: 1H-NMR (500 MHz, CDCl3) Spectrum of Compound 10 Figure S38: 13C-NMR (126 MHz, CDCl3) Spectrum of Compound 10 Figure S39: ESI-MS Spectrum of Compound 10 Figure S40: HRESI-MS Spectrum of Compound 10 Figure S41: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 11 Figure S42: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 11 Figure S43: ESI-MS Spectrum of Compound 11 Figure S44: HRESI-MS Spectrum of Compound 11 Figure S45: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 12 Figure S46: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 12 Figure S47: ESI-MS Spectrum of Compound 12 Figure S48: HRESI-MS Spectrum of Compound 12 Figure S49: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 13 Figure S50: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 13 Figure S51: ESI-MS Spectrum of Compound 13 Figure S52: HRESI-MS Spectrum of Compound 13 Figure S53: 1H-NMR (400 MHz, CDCl3) Spectrum of Compound 14 Figure S54: 13C-NMR (101 MHz, CDCl3) Spectrum of Compound 14 Figure S55: ESI-MS Spectrum of Compound 14 Figure S56: HRESI-MS Spectrum of Compound 14, Peer reviewed

The supporting information: Figure S1: SDS-PAGE patterns of OVA, OM, and LYS after in vitro gastroduodenal digestions. Electrophoresis was performed using Bis-Tris 12% acrylamide gel with reducing agents. Lanes: M, molecular mass marker (Bio Rad), ranging in molecular mass from 2 to 250 kDa; 1, OVA; 2, OVA digested; 3, OVA digested after treatment at 65 °C for 30 min; 4, OVA digested after treatment at 90 °C for 3 min; 5, OM; 6, OM digested; 7, OM digested after treatment at 65 °C for 30 min; 8, OM digested after treatment at 90 °C for 3 min; 9, LYS; 10, LYS digested; 11, LYS digested after treatment at 65 °C for 30 min; 12, LYS digested after treatment at 90 °C for 3 min; Table S1: Primer pair sequences and conditions used for the analyses of gene expression. References [35,36,37,38] are cited in the Supplementary File., Peer reviewed

Description of Additional Supplementary Files: File Name: Supplementary Data 1 Description: The file includes all statistics from linear regression model performed in the manuscript, including meqtl analysis. File Name: Supplementary Data 2 Description: Individual collected clinical information., Peer reviewed

In line with the European Food Safety Authority’s (EFSA) policy on openness and transparency, and in order for EFSA to receive comments on its work from the scientific community and stakeholders, EFSA engages in public consultations on key issues. Accordingly, EFSA carried out a public consultation to receive input from interested parties on the draft scientific opinion on the evaluation of existing guidelines for their adequacy for the food and feed risk assessment of plants obtained through synthetic biology. This draft scientific opinion was prepared by the EFSA GMO Panel, supported by a Working Group on Synthetic Biology of Genetically Modified Plants. The draft opinion was endorsed by the EFSA GMO Panel for public consultation on 1 December 2021. The online public consultation was open from 19 January 2022 until 20 March 2022 by means of an electronical comment submission tool together with explanatory text on the EFSA website (See Appendix A). EFSA received comments from 8 different interested parties. EFSA and its GMO Panel wish to thank all stakeholders for their contributions to this work. The present Annex contains the comments received and details how they have been considered for finalisation of the opinion. The final opinion was adopted at the GMO Panel Plenary meeting on 20 June 2022 and will be published in the EFSA Journal., Outcome of the public consultation on the draft scientific opinion on the Evaluation of existing guidelines for their adequacy for the food and feed risk assessment of genetically modified plants obtained through synthetic biology., Peer reviewed

The supporting information: Figure S1: Freeze-dried samples obtained from the cultivated mushrooms and employed in the analysis; Table S1: Percentage of the most-abundant VOCs detected in the freeze-dried samples by the optimized method based on SPME fiber extraction and GC-MS analysis., Peer reviewed